Sign In
30 Oct 2014 07:00
30 October 2014
ADVANCED ONCOTHERAPY Plc
("Advanced Oncotherapy" or the "Company")
Investor presentation
Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment,announces that it will be hosting an investor and analyst presentation on Tuesday 18 November 2014. The briefing will outline Advanced Oncotherapy's strategy and key milestones for the development and commercialisation of its proton therapy system: LIGHT (Linac for Image Guided Hadron Therapy).
The event will be held at the Royal Society of Medicine (1 Wimpole St, London W1G 0AE) with presentations beginning at 4pm, and will be followed by drinks and canapés at 5.30pm. The timetable for the event is as follows:
15:45 | Doors open
|
16:00 | Overview of Advanced Oncotherapy Sanjeev Pandya, CEO
|
16:15
16:30 | From CERN to the patient Steve Myers, Head of the Office of Medical Applications at CERN and former CERN's Director of Accelerators and Technology
Overview of the LIGHT accelerator Donatella Ungaro, Managing Director of ADAM
|
16.40 | LIGHT - A medical physicist perspective Professor Hanne Kooy, Department of Radiation Oncology of Harvard Medical School & Chairman of AVO's Product Development Committee
|
16.55 | Corporate milestones for a newly focussed business Sanjeev Pandya, CEO & Nicholas Serandour, CFO
|
17.10 | Q&As |
17.30 | Drinks & canapés |
To register to attend the event, or to receive further information on Advanced Oncotherapy, please contact Walbrook PR on 020 7933 8780 or email avo@walbrookpr.com.
For further information contact:
Advanced Oncotherapy Plc | www.avoplc.com |
Sanjeev Pandya, CEO | Tel: +44 20 3617 8726 |
Nicholas Serandour, CFO | Tel: +44 20 3757 8459 |
|
|
Westhouse Securities (Nomad & Joint Broker) | Tel: +44 20 7601 6100 |
Antonio Bossi / David Coaten |
|
|
|
Beaufort Securities (Joint Broker) | Tel: +44 20 7382 8300 |
Saif Janjua / Jon Levinson |
|
|
|
Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
Follow the stocks
